December 7, 2010 9:57 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(TheStreet) -- Biotech investors love the big score. No other sector but biotech offers investors the chance to pick up cheap or forgotten stocks that can turn hot and double, triple or even quadruple over the course of a year.Investors made a mint this year if they were smart or lucky enough to own one of the following five drug stock winners of 2010. No. 5: Questcor PharmaceuticalsSteeply priced drugs sold to a very small number of patients and reimbursed by insurers equal big profits for drug companies like Questcor (NASDAQ: QCOR). Acthar Gel, which Questcor sells for more than $23,000 per vial, is used to treat a rare form of epilepsy that strikes a couple of thousand babies each year.The stock: Questcor's stock price is up 195% this year through Dec. 2 because biotech and drug investors love growth. Questcor's earnings are expected to increase 55% this year and 47% in 2011.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.